Characterization of Genetic Variants of GIPR Reveals a Contribution of β-arrestin to Metabolic Phenotypes

Incretin-based therapies are highly successful in combatting obesity and type 2 diabetes. Yet both activation and inhibition of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) in combination with glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation have resulted in similar clinical outcomes, as demonstrated by the GIPR-GLP-1R co-agonist tirzepatide and AMG-133 (ref. ) combining GIPR antagonism with GLP-1R agonism. This underlines the importance of a better understanding of the GIP system. Here we show the necessity of β-arrestin recruitment for GIPR function, by combining in vitro pharmacological characterization of 47 GIPR variants with burden testing of clinical phenotypes and in vivo studies. Burden testing of variants with distinct ligand-binding capacity, Gs activation (cyclic adenosine monophosphate production) and β-arrestin 2 recruitment and internalization shows that unlike variants solely impaired in Gs signalling, variants impaired in both Gs and β-arrestin 2 recruitment contribute to lower adiposity-related traits. Endosomal Gs-mediated signalling of the variants shows a β-arrestin dependency and genetic ablation of β-arrestin 2 impairs cyclic adenosine monophosphate production and decreases GIP efficacy on glucose control in male mice. This study highlights a crucial impact of β-arrestins in regulating GIPR signalling and overall preservation of biological activity that may facilitate new developments in therapeutic targeting of the GIPR system.

Citing Articles

Rare MTNR1B variants causing diminished MT2 signalling associate with elevated HbA levels but not with type 2 diabetes.

Sorensen K, Justesen J, Angquist L, Bork-Jensen J, Hartmann B, Jorgensen N Diabetologia. 2025; .

PMID: 40064676 DOI: 10.1007/s00125-025-06381-y.

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.

Davies I, Adriaenssens A, Scott W, Carling D, Murphy K, Minnion J Mol Metab. 2025; 92:102094.

PMID: 39788289 PMC: 11786100. DOI: 10.1016/j.molmet.2025.102094.

Incretin hormones and obesity.

Alcaino C, Reimann F, Gribble F J Physiol. 2024; .

PMID: 39576749 PMC: 7617301. DOI: 10.1113/JP286293.

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354.

Rees T, Buttle B, Tasma Z, Yang S, Harris P, Walker C Front Pharmacol. 2024; 15:1463313.

PMID: 39464637 PMC: 11502443. DOI: 10.3389/fphar.2024.1463313.

New insights into the regulation of GIPR signalling.

Manchanda Y, Tomas A Nat Rev Endocrinol. 2024; 20(10):571-572.

PMID: 39174673 DOI: 10.1038/s41574-024-01027-2.

References

Gabe M, Sparre-Ulrich A, Pedersen M, Gasbjerg L, Inoue A, Brauner-Osborne H . Human GIP(3-30)NH inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochem Pharmacol. 2018; 150:97-107. DOI: 10.1016/j.bcp.2018.01.040. View

Gao R, Liu Y, Gjesing A, Hollensted M, Wan X, He S . Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model. BMC Genet. 2014; 15:13. PMC: 3943834. DOI: 10.1186/1471-2156-15-13. View

Turcot V, Lu Y, Highland H, Schurmann C, Justice A, Fine R . Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet. 2017; 50(1):26-41. PMC: 5945951. DOI: 10.1038/s41588-017-0011-x. View

Glumer C, Jorgensen T, Borch-Johnsen K . Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003; 26(8):2335-40. DOI: 10.2337/diacare.26.8.2335. View

Roed S, Wismann P, Underwood C, Kulahin N, Iversen H, Cappelen K . Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol. 2013; 382(2):938-49. DOI: 10.1016/j.mce.2013.11.010. View

Wan Q, Okashah N, Inoue A, Nehme R, Carpenter B, Tate C . Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. J Biol Chem. 2018; 293(19):7466-7473. PMC: 5949987. DOI: 10.1074/jbc.RA118.001975. View

Bycroft C, Freeman C, Petkova D, Band G, Elliott L, Sharp K . The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018; 562(7726):203-209. PMC: 6786975. DOI: 10.1038/s41586-018-0579-z. View

Kircher M, Witten D, Jain P, ORoak B, Cooper G, Shendure J . A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46(3):310-5. PMC: 3992975. DOI: 10.1038/ng.2892. View

Kizilkaya H, Sorensen K, Kibsgaard C, Gasbjerg L, Hauser A, Sparre-Ulrich A . Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes. Front Cell Dev Biol. 2021; 9:749607. PMC: 8573201. DOI: 10.3389/fcell.2021.749607. View

10.

Holm J, Gamborg M, Bille D, Gr Nb K H, Ward L, Faerk J . Chronic care treatment of obese children and adolescents. Int J Pediatr Obes. 2011; 6(3-4):188-96. DOI: 10.3109/17477166.2011.575157. View

11.

Millard L, Davies N, Gaunt T, Davey Smith G, Tilling K . Software Application Profile: PHESANT: a tool for performing automated phenome scans in UK Biobank. Int J Epidemiol. 2017; 47(1):29-35. PMC: 5837456. DOI: 10.1093/ije/dyx204. View

12.

Akbari P, Gilani A, Sosina O, Kosmicki J, Khrimian L, Fang Y . Sequencing of 640,000 exomes identifies variants associated with protection from obesity. Science. 2021; 373(6550). PMC: 10275396. DOI: 10.1126/science.abf8683. View

13.

Flannick J, Mercader J, Fuchsberger C, Udler M, Mahajan A, Wessel J . Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019; 570(7759):71-76. PMC: 6699738. DOI: 10.1038/s41586-019-1231-2. View

14.

Wisler J, Harris E, Raisch M, Mao L, Kim J, Rockman H . The role of β-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome. Am J Physiol Heart Circ Physiol. 2015; 309(9):H1516-27. PMC: 4666970. DOI: 10.1152/ajpheart.00291.2015. View

15.

Lotta L, Mokrosinski J, Mendes de Oliveira E, Li C, Sharp S, Luan J . Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. Cell. 2019; 177(3):597-607.e9. PMC: 6476272. DOI: 10.1016/j.cell.2019.03.044. View

16.

Jorgensen T, Borch-Johnsen K, Thomsen T, Ibsen H, Glumer C, Pisinger C . A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil. 2003; 10(5):377-86. DOI: 10.1097/01.hjr.0000096541.30533.82. View

17.

van der Velden W, Smit F, Christiansen C, Moller T, Hjorto G, Larsen O . GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. ACS Pharmacol Transl Sci. 2021; 4(1):296-313. PMC: 7887852. DOI: 10.1021/acsptsci.0c00193. View

18.

Prive F, Aschard H, Carmi S, Folkersen L, Hoggart C, OReilly P . Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am J Hum Genet. 2022; 109(1):12-23. PMC: 8764121. DOI: 10.1016/j.ajhg.2021.11.008. View

19.

McLaren W, Gil L, Hunt S, Riat H, Ritchie G, Thormann A . The Ensembl Variant Effect Predictor. Genome Biol. 2016; 17(1):122. PMC: 4893825. DOI: 10.1186/s13059-016-0974-4. View

20.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View